INAB
INAB clinical trials: IN8BIO, INC.
Every trial on ClinicalTrials.gov where IN8BIO, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 2
- Trials linked
- 1
- As lead sponsor
- 1
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
INAB on the catalyst calendar · INAB registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2026Sponsor estimate | NCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination...In8bio Inc. · Glioblastoma | INABLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 2027Sponsor estimate | NCT03533816Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideUniversity of Kansas Medical Center · Acute Myeloid Leukemia | INABCollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination...In8bio Inc. · GlioblastomaActive, not recruitingINABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT03533816Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideUniversity of Kansas Medical Center · Acute Myeloid LeukemiaRecruitingINABCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 2 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner